Loading...
XPAR
AB
Market cap76mUSD
Jun 09, Last price  
1.18EUR
1D
1.72%
1Q
-14.49%
Jan 2017
-91.37%
IPO
-90.69%
Name

AB Science SA

Chart & Performance

D1W1MN
P/E
—
P/S
69.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.54%
Rev. gr., 5y
-10.63%
Revenues
970k
+1.25%
316,000917,0001,104,0001,340,0001,933,0002,099,0002,284,0001,508,0001,739,0001,701,0001,571,0001,583,0001,607,000958,000970,000
Net income
-10m
L-26.20%
-8,110,000-9,489,000-9,651,000-10,985,000-14,611,000-16,112,000-26,716,000-27,696,000-27,122,000-26,061,000-21,748,000-15,045,000-14,463,000-13,615,000-10,048,000
CFO
-17m
L-3.43%
-7,766,000-7,863,000-8,320,000-6,211,000-12,835,000-14,158,000-23,155,000-33,520,000-22,896,000-26,792,000-15,156,000-13,511,000-17,178,000-17,471,000-16,871,000
Earnings
Sep 29, 2025

Profile

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
URL
https://www.ab-science.com/
IPO date
Apr 21, 2010
Employees
103
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
970
1.25%
958
-40.39%
Cost of revenue
12,700
15,531
Unusual Expense (Income)
NOPBT
(11,730)
(14,573)
NOPBT Margin
Operating Taxes
1,000
4
Tax Rate
NOPAT
(11,731)
(14,577)
Net income
(10,048)
-26.20%
(13,615)
-5.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,474
4
BB yield
Debt
Debt current
2,113
4,664
Long-term debt
17,491
20,351
Deferred revenue
Other long-term liabilities
10,929
17,139
Net debt
13,454
17,672
Cash flow
Cash from operating activities
(16,871)
(17,471)
CAPEX
(345)
(644)
Cash from investing activities
(614)
(360)
Cash from financing activities
16,274
16,391
FCF
(11,251)
(14,252)
Balance
Cash
6,066
7,269
Long term investments
84
74
Excess cash
6,102
7,295
Stockholders' equity
(286,939)
(269,597)
Invested Capital
295,868
274,487
ROIC
ROCE
EV
Common stock shares outstanding
68,200
47,139
Price
Market cap
EV
EBITDA
(9,459)
(14,654)
EV/EBITDA
Interest
3,960
2,016
Interest/NOPBT